AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 86 filers reported holding AVADEL PHARMACEUTICALS PLC in Q4 2021. The put-call ratio across all filers is 0.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $223,304 | -94.7% | 21,680 | -91.6% | 0.00% | -100.0% |
| Q2 2023 | $4,252,664 | +1692.6% | 258,050 | +896.4% | 0.00% | – |
| Q1 2023 | $237,235 | -55.8% | 25,899 | -65.4% | 0.00% | – |
| Q4 2022 | $536,277 | +562.1% | 74,899 | +125.5% | 0.00% | – |
| Q2 2022 | $81,000 | -72.3% | 33,220 | -22.4% | 0.00% | – |
| Q1 2022 | $292,000 | -78.3% | 42,804 | -74.3% | 0.00% | – |
| Q4 2021 | $1,348,000 | +164.3% | 166,869 | +220.9% | 0.00% | – |
| Q3 2021 | $510,000 | +335.9% | 52,000 | +198.9% | 0.00% | – |
| Q2 2021 | $117,000 | -89.3% | 17,397 | -85.6% | 0.00% | – |
| Q1 2021 | $1,094,000 | +835.0% | 121,005 | +589.7% | 0.00% | – |
| Q4 2020 | $117,000 | +23.2% | 17,545 | +50.0% | 0.00% | – |
| Q2 2020 | $95,000 | +66.7% | 11,700 | -15.3% | 0.00% | – |
| Q3 2019 | $57,000 | – | 13,819 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
| COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
| GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
| Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
| Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
| Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
| Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
| Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
| RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
| FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |